ALKU and Holland Square Group (HSG), an ALKU Company, are excited to announce that HSG’s Security Division will operate completely as ALKU in the new year!
Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals.
Veristat, a full-service Clinical Research Organization (CRO), announced today that it has partnered with Triumph Research Intelligence (TRI), a global leader providing technology and solutions for centralized and risk-based monitoring (RBM) to improve clinical trial quality and compliance.
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.
Acquia and BigCommerce today announced a partnership to help merchants develop and launch online ecommerce solutions with powerful, on-brand customer experiences.
Acquia and Elastic Path today announce a partnership to help brands realize the opportunities of open source content management and headless commerce solutions.
BrainSell Technologies, a value-added reseller (VAR) that specializes in end-to-end business software technologies and unbiased consulting and implementation services for organizations of all sizes, today announced a new partnership with HubWise Technology.
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer.
ALKU a highly specialized consulting services firm, has expanded their niche industries to include ServiceNow contract services.
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.